Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 631 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1100
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
Jingxuan Quek, Kai En Chan, Zhen Yu Wong, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 20-30
Closed Access | Times Cited: 326
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 310
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 248
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 235
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 841-850
Open Access | Times Cited: 158
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
Michael H. Le, David M. Le, Thomas C. Baez, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 287-295
Closed Access | Times Cited: 153
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 144
Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 11, pp. 708-722
Closed Access | Times Cited: 125
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
Zobair M. Younossi, James M. Paik, Maria Stepanova, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. 694-701
Closed Access | Times Cited: 122
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
Jie Fang, Chen-Huan Yu, Xuejian Li, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 95
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
Julia Wattacheril, Manal F. Abdelmalek, Joseph K. Lim, et al.
Gastroenterology (2023) Vol. 165, Iss. 4, pp. 1080-1088
Open Access | Times Cited: 90
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A. Harrison, Juan P. Frías, Guy Neff, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 12, pp. 1080-1093
Closed Access | Times Cited: 81
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Monica A. Tincopa, Rohit Loomba
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 660-670
Closed Access | Times Cited: 77
The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
James M. Paik, Linda Henry, Youssef Younossi, et al.
Hepatology Communications (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 76
Clinical Trial Landscape in NASH
Stephen A. Harrison, Rohit Loomba, Julie Dubourg, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2001-2014
Closed Access | Times Cited: 74
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1524-1541
Open Access | Times Cited: 74
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 5, pp. 575-594
Open Access | Times Cited: 73
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard, et al.
Diabetes Care (2023) Vol. 46, Iss. 7, pp. 1354-1362
Open Access | Times Cited: 71
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 70
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, et al.
Metabolism (2024) Vol. 154, pp. 155835-155835
Open Access | Times Cited: 67
Applications of synthetic biology in medical and pharmaceutical fields
Xu Yan, Xu Liu, Cuihuan Zhao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 64
Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults
Xinyuan Zhang, Longgang Zhao, Alan Ducatman, et al.
JHEP Reports (2023) Vol. 5, Iss. 5, pp. 100694-100694
Open Access | Times Cited: 57
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD
Vlad Ratziu, Jérôme Boursier, Victor de Lédinghen, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. e51-e52
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top